In an unexpected turn of events, Bausch Health Companies made a significant announcement on September 19, 2023. Tom Vadaketh, the esteemed Executive Vice President and CFO, has decided to step down from his position, bidding farewell to the company on October 13. This surprising development had an immediate impact on the market, as BHC shares experienced a noticeable decline of approximately 3% during premarket trading on Tuesday.
However, Bausch Health Companies swiftly devised a plan to ensure the smooth functioning of their financial operations during this transitional period. John Barresi, a highly capable individual who currently holds the position of Bausch’s controller and chief accounting officer, will assume the responsibilities of interim CFO if no suitable successor is appointed before Vadaketh’s departure.
This unexpected change in leadership has created an air of uncertainty within the company and the market as a whole. As Bausch Health Companies navigates this transition, all eyes will be on the selection process for a new CFO and the subsequent impact on the company’s future endeavors.
Bausch Health Companies Inc.
BHC
Neutral
Updated on: 29/09/2023
Financial Health
Weak
Debt to equity ratio: Strong Sell
Price to earnings ratio: Sell
Price to book ratio: Strong Sell
DCF: Strong Buy
ROE: Strong Buy
BHC Stock Performance Analysis: Declining Earnings and Revenue Growth Raise Concerns
BHC’s stock performance on September 19, 2023, showed a lower opening price of $8.09 compared to the previous day’s close of $8.37. The stock price fluctuated between $7.56 and $8.10 throughout the day. The trading volume was significantly higher than the average volume of the past three months, with 10,085,275 shares traded. BHC’s market capitalization stood at $3.1 billion.
BHC had a positive earnings growth rate of 76.47% last year, but this year’s growth has declined by 2.91%. The company is expected to experience a further decline in earnings growth over the next five years, with a projected growth rate of -4.29%.
Similarly, BHC’s revenue growth has declined by 3.68% in the previous year. This indicates a challenging business environment for the company, which operates in the Health Technology sector and falls under the Pharmaceuticals: Major industry.
The price-to-earnings (P/E) ratio for BHC is not available (NM), suggesting that the company may not have positive earnings or may have negative earnings. The price-to-sales ratio stands at 0.28, indicating that investors are paying $0.28 for every dollar of the company’s sales.
BHC’s stock showed a slight decline of 0.05 on September 19, 2023, resulting in a percentage change of -0.23%. Indivior PLC experienced a similar decrease, while Madrigal Pharmaceuticals saw an increase of 5.68 and Cytokinetics Inc had a decline of 0.92.
BHC’s next reporting date is scheduled for November 7, 2023, with analysts forecasting earnings per share (EPS) of $0.91 for this quarter. In the previous year, BHC generated annual revenue of $8.1 billion but reported a net loss of $225.0 million. The net profit margin for the company currently stands at -2.77%.
BHC operates in the Health Technology sector and has no listed executives. The company’s corporate headquarters are located in Laval, Québec.
In summary, BHC’s stock performance on September 19, 2023, was characterized by a lower opening price, fluctuating stock price, and declines in earnings growth and revenue growth. Investors should closely monitor BHC’s financial performance and upcoming earnings report on November 7, 2023, to gain a better understanding of its future prospects.
Bausch Health Companies Inc (BHC) Stock Analysis: Potential Increase of 9.96% and Consensus to Hold
On September 19, 2023, Bausch Health Companies Inc (BHC) stock had a last price of 7.73. The median target for BHC stock is 8.50, with a high estimate of 12.00 and a low estimate of 6.00. This indicates a potential increase of 9.96% from the last price. The consensus among seven polled investment analysts is to hold stock in Bausch Health Companies Inc. Bausch Health Companies Inc reported earnings per share of $0.91 and sales of $2.1 billion. The reporting date for these figures is November 7.
Discussion about this post